NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said it has commenced its tender offer to buy all of Biosite's outstanding shares at a price of $92.50 per share without interest.
Under the cash deal, Inverness would pay an additional $.015205 per share for each day after July 2 that the shares are not accepted for payment.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.